(Q34424500)

2 August 2017

title

PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges (English)

1 reference

2 August 2017

0 references

Giuseppe Danilo Norata

object named as

Giuseppe Danilo Norata

series ordinal

1

0 references

Alberico L. Catapano

object named as

Alberico Luigi Catapano

series ordinal

3

0 references

author name string

Gianpaolo Tibolla

series ordinal

2

1 reference

2 August 2017

language of work or name

1 reference

9 June 2014

1 reference

2 August 2017

published in

Vascular Pharmacology

1 reference

2 August 2017

volume

62

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

103-111

1 reference

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Targeting PCSK9 for hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

The self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated low density lipoprotein receptor degradation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

In vivo evidence that furin from hepatocytes inactivates PCSK9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Genetic and metabolic determinants of plasma PCSK9 levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

A new method for measurement of total plasma PCSK9: clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Lack of a relationship between plasma PCSK9 concentrations and hepatic lipoprotein kinetics in obese people

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Plasma proprotein convertase subtilisin kexin type 9 is a heritable trait of familial combined hyperlipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

PCSK9 is expressed in pancreatic delta-cells and does not alter insulin secretion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

PCSK9 is present in human cerebrospinal fluid and is maintained at remarkably constant concentrations throughout the course of the day.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

LRP: role in vascular wall integrity and protection from atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

The low-density lipoprotein receptor-related protein 1 in inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Adipocyte LDL receptor-related protein-1 expression modulates postprandial lipid transport and glucose homeostasis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Gene silencing approaches for the management of dyslipidaemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2014.05.011

10.1016/J.VPH.2014.05.011

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference